Bering Partners II, L.P. - 05 Sep 2025 SCHEDULE 13G Report for Coherus Oncology, Inc. Common Stock, $0.0001 par value per share (CHRS)

Quoteable Key Fact

"Bering Partners II, L.P. disclosed 6.5% ownership in Coherus Oncology, Inc. Common Stock, $0.0001 par value per share (CHRS) on 05 Sep 2025."

Quick Takeaways

Bering Partners II, L.P. filed SCHEDULE 13G for Coherus Oncology, Inc. Common Stock, $0.0001 par value per share (CHRS).
Disclosed ownership: 6.5%.
Date of event: 05 Sep 2025.

This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
You can verify ownership claims directly against the original SEC filing.

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

Name	Ownership	Shares Owned	sole voting power	shared voting power	Signature	Title
Bering Partners II, L.P. ("Bering II")	4.1%	4,763,062	4,763,062	0	/s/ Evgeny Zaytsev	Managing Member of the General Partner
Bering Partners II GP, L.L.C. ("Bering II GP")	4.1%	4,763,062	4,763,062	0	/s/ Evgeny Zaytsev	Managing Member
Bering Partners III, L.P. ("Bering III")	2.4%	2,826,446	2,826,446	0	/s/ Evgeny Zaytsev	Managing Member of the General Partner
Bering Partners III GP, L.L.C. ("Bering III GP")	2.4%	2,826,446	2,826,446	0	/s/ Evgeny Zaytsev	Managing Member
Evgeny Zaytsev ("Zaytsev")	6.5%	7,602,708	13,200	7,589,508	/s/ Evgeny Zaytsev	Evgeny Zaytsev
Philip Sawyer ("Sawyer")	6.5%	7,589,508	0	7,589,508	/s/ Philip Sawyer	Philip Sawyer